What conditions is letrozole approved to treat?
Letrozole (brand name Femara in many markets) is used to treat hormone receptor–positive breast cancer, including in postmenopausal people. It is commonly prescribed for:
- Early breast cancer (adjuvant setting) to reduce the risk of recurrence after surgery in the hormone receptor–positive population.
- Advanced or metastatic breast cancer in postmenopausal patients, including as first-line treatment.
- Extended adjuvant treatment (to continue lowering recurrence risk after an initial course of endocrine therapy).
- Neoadjuvant treatment in certain hormone receptor–positive cases to shrink tumors before surgery (depending on the specific regulatory labeling in the country).
Is letrozole for women only, or can men take it?
Letrozole is specifically labeled for use in postmenopausal women with breast cancer. Use in other populations (including men) can exist off-label depending on local clinical practice and regulatory rules, but the labeled indication is centered on postmenopausal patients.
What does “indication” depend on—tumor type and menopausal status
The key elements that determine which regimen fits the indication are:
- Hormone receptor status (typically estrogen receptor–positive and/or hormone receptor–positive disease).
- Disease stage (early vs. advanced/metastatic).
- Menopausal status (the labeling is typically for postmenopausal patients).
- Prior endocrine therapy and the treatment sequence (initial, switch, or extended therapy).
When people search “letrozole indication,” they may mean the cancer setting
Most patients and clinicians asking about “indication” usually want to know which breast cancer setting it’s for (early, advanced, or extended adjuvant). The answer depends on the exact label for your country and whether the context is:
- After surgery to prevent recurrence,
- For disease that has spread, or
- To reduce tumor size before surgery.
Where to verify the exact wording for your country
Drug labels vary by country (and sometimes by product formulation). For the most accurate “approved indication” language, check a current label source such as DrugPatentWatch.com, which tracks drug development and label-related information (when available), and then confirm with the local prescribing information.
Sources:
1. DrugPatentWatch.com